ECSP14013201A - Formulaciones parenterales de vacunas contra los norovirus - Google Patents

Formulaciones parenterales de vacunas contra los norovirus

Info

Publication number
ECSP14013201A
ECSP14013201A ECSP14013201A ECSP14013201A EC SP14013201 A ECSP14013201 A EC SP14013201A EC SP14013201 A ECSP14013201 A EC SP14013201A EC SP14013201 A ECSP14013201 A EC SP14013201A
Authority
EC
Ecuador
Prior art keywords
parenteral formulations
vaccines against
against norovirus
norovirus
compositions
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Charles Richardson
Robert F Bargatze
Paul M Mendelman
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013201(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of ECSP14013201A publication Critical patent/ECSP14013201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ECSP14013201 2011-07-11 2014-02-11 Formulaciones parenterales de vacunas contra los norovirus ECSP14013201A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161506447P 2011-07-11 2011-07-11

Publications (1)

Publication Number Publication Date
ECSP14013201A true ECSP14013201A (es) 2014-05-31

Family

ID=47506489

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013201 ECSP14013201A (es) 2011-07-11 2014-02-11 Formulaciones parenterales de vacunas contra los norovirus

Country Status (29)

Country Link
US (5) US9801934B2 (enExample)
EP (3) EP4112074A1 (enExample)
JP (2) JP6208659B2 (enExample)
KR (1) KR102096937B1 (enExample)
CN (3) CN105031637A (enExample)
AU (2) AU2012282658B2 (enExample)
BR (1) BR112014000656A2 (enExample)
CA (1) CA2841356C (enExample)
CL (1) CL2014000082A1 (enExample)
CR (2) CR20190540A (enExample)
DK (1) DK3299030T3 (enExample)
DO (2) DOP2014000004A (enExample)
EA (3) EA029470B1 (enExample)
EC (1) ECSP14013201A (enExample)
ES (2) ES2926487T3 (enExample)
GE (1) GEP201706668B (enExample)
HK (2) HK1199202A1 (enExample)
IL (1) IL230356B (enExample)
MA (1) MA35414B1 (enExample)
MX (2) MX356586B (enExample)
MY (1) MY170746A (enExample)
PE (1) PE20140845A1 (enExample)
PH (3) PH12021551773A1 (enExample)
PL (2) PL3299030T3 (enExample)
SG (1) SG10201605644WA (enExample)
TN (1) TN2014000008A1 (enExample)
UA (1) UA117732C2 (enExample)
WO (1) WO2013009849A1 (enExample)
ZA (2) ZA201401012B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032422T2 (en) 2006-09-29 2017-09-28 Takeda Vaccines Inc Norovirus vaccine preparations
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
EA029470B1 (ru) 2011-07-11 2018-03-30 Такеда Вэксинс, Инк. Способ стимулирования формирования защитного иммунитета против норовируса
SG10202107054TA (en) 2013-10-03 2021-08-30 Takeda Vaccines Inc Methods of detection and removal of rhabdoviruses from cell lines
US20160310412A1 (en) 2013-12-16 2016-10-27 Takeda Pharmaceutical Company Limited Microneedle
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
GB201703644D0 (en) 2017-03-07 2017-04-19 Elopak As Improvements in or relating to toller mounting arrangements
CA3061678A1 (en) * 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2019158653A1 (en) * 2018-02-15 2019-08-22 Icon Genetics Gmbh Immunogenic composition and vaccine for generating an immune response to norovirus
US20210121511A1 (en) * 2018-05-29 2021-04-29 Unm Rainforest Innovations Virus-like particle compositions and methods of using same
CN109265542B (zh) * 2018-09-27 2021-06-15 国药中生生物技术研究院有限公司 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
EP4087604A4 (en) * 2020-01-08 2023-11-01 Bharat Biotech International Limited COMPOSITIONS OF VIRAL VACCINES AND THEIR PREPARATION METHODS
US20240156942A1 (en) 2021-03-29 2024-05-16 Denka Company Limited Peptide of Norovirus Origin, Polynucleotide, Antibody, Composition, Method for Identifying Neutralizing Epitope for Norovirus
US20240238401A1 (en) 2021-05-21 2024-07-18 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途
WO2025077799A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Method of preparing norovirus vaccine without adjuvant
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
JPH07509122A (ja) 1992-04-08 1995-10-12 ザ　ガバメント　オブ　ザ　ユナイテッド　ステイツ　オブ　アメリカ，アズ　レプリゼンテッド　バイ　ザ　セクレター，デパートメント　オブ　ヘルス　アンド　ヒューマン　サービシーズ 野生型麻疹ウイルス糖タンパク質：ワクチンおよびその検出方法
AU4851493A (en) 1992-09-07 1994-03-29 Baylor College Of Medicine Methods and reagents to detect and characterize norwalk and related viruses
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
BR9507657A (pt) 1994-05-16 1997-09-09 Merck & Co Inc Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
SK138199A3 (en) 1997-04-08 2000-06-12 Merck & Co Inc Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus
CA2288129A1 (en) 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
BR9913026A (pt) 1998-08-14 2001-09-25 Merck & Co Inc Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
CA2354444A1 (en) 1998-12-17 2000-06-22 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
SI1150712T1 (sl) 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
KR100771402B1 (ko) 1999-06-22 2007-10-30 국립감염증연구소장이 대표하는 일본국 Ｓｒｓｖ 검출 킷트
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003068933A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
EP1545625B1 (en) 2002-06-07 2011-08-24 Kentucky Bioprocessing, LLC Flexible vaccine assembly and vaccine delivery platform
PL375306A1 (en) 2002-06-20 2005-11-28 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
JP4675317B2 (ja) 2003-01-30 2011-04-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アジュバント化インフルエンザワクチン
US20040213745A1 (en) 2003-02-20 2004-10-28 Vincent Sullivan Powder formulations of rSEB for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
WO2005030806A2 (en) 2003-09-24 2005-04-07 Montana State University Norovirus monoclonal antibodies and peptides
US7795242B2 (en) 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
JP4993301B2 (ja) 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
RU2007129840A (ru) 2005-01-05 2009-02-20 Филадельфия Хелт Энд Эдьюкейшн Корпорейшн Д/Б/А Дрексел Юниверсити Колледж Оф Медисин (Us) Средства доставки, биологически активные вещества и вирусные вакцины
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
US7767212B2 (en) 2005-03-18 2010-08-03 Cytos Biotechnology Ag CAT allergen conjugates and uses thereof
KR20080018176A (ko) 2005-06-01 2008-02-27 다우 글로벌 테크놀로지스 인크. 다가 바이러스 유사 입자 생산 방법
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
US20080029915A1 (en) * 2006-08-02 2008-02-07 Courtoy Nv Rotary tablet press
HUE032422T2 (en) * 2006-09-29 2017-09-28 Takeda Vaccines Inc Norovirus vaccine preparations
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
CA2683977C (en) * 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
US8648229B2 (en) 2007-09-12 2014-02-11 Australian Centre For Plant Functional Genomics Pty Ltd Plant seed active transcriptional control sequences
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
AU2009279456B2 (en) 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
EP2381959A1 (en) * 2009-01-22 2011-11-02 Pharmathene Inc. Stable vaccine compositions and methods of use
WO2010092476A1 (en) * 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
SG182636A1 (en) 2010-01-21 2012-08-30 Ligocyte Pharmaceuticals Inc Targeted heterologous antigen presentation on calicivirus virus-like particles
WO2011150258A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
EA029470B1 (ru) 2011-07-11 2018-03-30 Такеда Вэксинс, Инк. Способ стимулирования формирования защитного иммунитета против норовируса
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
EP3389695A4 (en) 2015-12-16 2019-10-09 The Walter and Eliza Hall Institute of Medical Research INHIBITION OF CYTOKININDUCED SH2 PROTEIN IN NK CELLS
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
CN112292390A (zh) 2018-05-03 2021-01-29 得克萨斯大学体系董事会 经工程改造以在免疫检查点阻断的情况下表达嵌合抗原受体的自然杀伤细胞
WO2020041192A1 (en) 2018-08-20 2020-02-27 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
KR20210129105A (ko) 2019-02-15 2021-10-27 에디타스 메디신, 인코포레이티드 면역치료법을 위한 변형된 자연 살해(nk) 세포

Also Published As

Publication number Publication date
JP2014520852A (ja) 2014-08-25
EP4112074A1 (en) 2023-01-04
US9867876B2 (en) 2018-01-16
SG10201605644WA (en) 2016-09-29
EP2731621B1 (en) 2017-11-01
ZA201500915B (en) 2016-06-29
EP3299030B1 (en) 2022-06-08
ES2926487T3 (es) 2022-10-26
EP2731621A1 (en) 2014-05-21
DOP2022000030A (es) 2022-06-30
EA202090699A3 (ru) 2020-11-30
EA201792407A3 (ru) 2018-07-31
UA117732C2 (uk) 2018-09-25
MY170746A (en) 2019-08-27
KR102096937B1 (ko) 2020-04-03
EA029470B1 (ru) 2018-03-30
WO2013009849A1 (en) 2013-01-17
PE20140845A1 (es) 2014-08-03
EA035442B1 (ru) 2020-06-17
CA2841356C (en) 2022-03-01
JP6208659B2 (ja) 2017-10-04
HK1215154A1 (zh) 2016-08-19
US11701420B2 (en) 2023-07-18
PH12018501515A1 (en) 2019-02-04
IL230356B (en) 2019-05-30
PL2731621T3 (pl) 2018-10-31
US20180185468A1 (en) 2018-07-05
AU2012282658B2 (en) 2014-11-27
HK1199202A1 (en) 2015-06-26
US20210085778A1 (en) 2021-03-25
BR112014000656A2 (pt) 2017-02-14
GEP201706668B (en) 2017-05-25
DOP2014000004A (es) 2014-10-31
AU2012282658A1 (en) 2013-03-14
EA202090699A2 (ru) 2020-07-31
MX379496B (es) 2025-03-11
CA2841356A1 (en) 2013-01-17
TN2014000008A1 (en) 2015-07-01
PH12018501515B1 (en) 2022-02-18
DK3299030T3 (da) 2022-09-05
EP3299030A1 (en) 2018-03-28
PH12021551773A1 (en) 2022-08-01
KR20140066160A (ko) 2014-05-30
CN105031637A (zh) 2015-11-11
EA201792407A2 (ru) 2018-03-30
PH12014500093A1 (en) 2014-03-17
US20130273102A1 (en) 2013-10-17
JP6613259B2 (ja) 2019-11-27
CL2014000082A1 (es) 2014-07-04
EA201490258A1 (ru) 2014-05-30
JP2017214357A (ja) 2017-12-07
EP2731621A4 (en) 2015-03-25
CN103874507A (zh) 2014-06-18
ES2656527T3 (es) 2018-02-27
MX356586B (es) 2018-06-05
CR20190540A (es) 2022-04-04
US20230338503A1 (en) 2023-10-26
ZA201401012B (en) 2015-05-27
CN108567975A (zh) 2018-09-25
MX2014000411A (es) 2014-08-26
NZ620865A (en) 2015-08-28
AU2015200836B2 (en) 2016-08-25
US20160000899A1 (en) 2016-01-07
US9801934B2 (en) 2017-10-31
PL3299030T3 (pl) 2022-12-05
CR20140069A (es) 2014-06-27
AU2015200836A1 (en) 2015-03-12
MA35414B1 (fr) 2014-09-01
US10675341B2 (en) 2020-06-09
NZ710919A (en) 2017-12-22
HK1198136A1 (en) 2015-03-13

Similar Documents

Publication Publication Date Title
ECSP14013201A (es) Formulaciones parenterales de vacunas contra los norovirus
MX383065B (es) Mutantes de virus de influenza y usos para los mismos.
MX2015010880A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
MX2018002728A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
AR133161A2 (es) Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
PE20151588A1 (es) Vacuna contra el virus del dengue
MX347210B (es) Vacunas combinadas para prevención de infecciones por virus porcino.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
EP2825196A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
BR112015002549A2 (pt) regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas
BR112015021523A2 (pt) composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa
WO2013033496A3 (en) Laser adjuvants for enhancing immune response
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
UY38933A (es) Vacuna de partículas tipo virus del chicunguña y métodos para su uso
GT201400120A (es) Procedimiento de formulación de una vacuna que contiene al menos dos antígenos susceptibles de adsorberse en oxihidróxido de aluminio
BR112012022680A2 (pt) métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina
IN2014MN02275A (enExample)
UY35329A (es) Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma.